Valuation

SNSmith & Nephew plc

StockLSEUnited KingdomHealth careEU retail: available

−0.3% today · −18.7% over a year

6/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 62% of the instruments we score

Trend: among the weakest; priced lower than most peers. Dividend yield 2.64%.

Smith & Nephew plc (SN) valuation against sector peers: P/E 20.9 (sector median 22.4), P/B 2.5, EV/EBIT 19.7, free-cash-flow yield 6.5%, P/S 2.1.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricSNSector medianvs median
P/E20.922.4 · n=287% below
P/B2.53.6 · n=4531% below
P/S2.14.5 · n=4053% below
EV/EBIT19.720.8 · n=286% below
Free-cash-flow yield6.5%3.5% · n=4189% above
Dividend yield2.64%0.12% · n=1002,110% above
Return on equity11.8%6.8% · n=5675% above
Return on invested capital8.2%7.0% · n=4716% above
Gross margin68.0%70.2% · n=39near the median
Net debt / EBITDA—1.39 · n=26—

Value factor: 73 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG21.36.517.95.9%2.5%9/10
NOVNNovartis AG21.26.417.85.9%2.9%10/10
AZNAstraZeneca plc25.75.420.94.5%1.9%6/10
AZNAstraZeneca PLC25.75.420.94.5%1.3%6/10
NVONovo Nordisk A/S11.25.99.85.2%4.8%7/10
GSKGSK plc13.84.811.38.1%3.7%10/10
SNYSanofi11.81.316.37.8%5.0%7/10
SANSanofi SA11.81.316.27.8%5.5%8/10
TEVATeva Pharmaceutical Industries Limited66.06.037.22.9%0.0%6/10
ALCAlcon34.71.527.35.1%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 16 Mar 2026